Gazyvaro, known generically as obinutuzumab, is a monoclonal antibody medication primarily used in the treatment of certain types of blood cancers, including chronic lymphocytic leukemia (CLL) and follicular lymphoma. It works by targeting and binding to the CD20 protein found on the surface of B cells (a type of white blood cell), which plays a role in the development and progression of these cancers. By attaching to these cells, Gazyvaro helps the immune system to identify and destroy them, thereby reducing the number of cancerous cells in the body. It is often used in combination with other chemotherapy drugs to enhance its effectiveness. Gazyvaro is administered through intravenous infusion, and its use may be associated with a range of side effects, from mild to severe, necessitating careful monitoring by healthcare professionals during treatment.